Compare ELS & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ELS | IONS |
|---|---|---|
| Founded | 1992 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 12.1B |
| IPO Year | 1994 | 1996 |
| Metric | ELS | IONS |
|---|---|---|
| Price | $61.29 | $47.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 22 |
| Target Price | $70.25 | ★ $93.36 |
| AVG Volume (30 Days) | 1.2M | ★ 2.6M |
| Earning Date | 04-21-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.49% | N/A |
| EPS Growth | 2.55 | ★ 21.71 |
| EPS | ★ 0.56 | N/A |
| Revenue | ★ $1,531,382,000.00 | N/A |
| Revenue This Year | $3.97 | N/A |
| Revenue Next Year | $4.69 | $77.99 |
| P/E Ratio | $107.29 | ★ N/A |
| Revenue Growth | ★ 0.34 | N/A |
| 52 Week Low | $58.72 | $50.01 |
| 52 Week High | $69.00 | $86.74 |
| Indicator | ELS | IONS |
|---|---|---|
| Relative Strength Index (RSI) | 38.85 | 30.30 |
| Support Level | $61.22 | $50.64 |
| Resistance Level | $63.83 | $57.48 |
| Average True Range (ATR) | 0.93 | 1.99 |
| MACD | -0.33 | -0.82 |
| Stochastic Oscillator | 30.82 | 2.02 |
Equity Lifestyle Properties is a residential REIT that focuses on owning manufactured housing, residential vehicle communities, and marinas. The company has a portfolio of 453 properties across the US with a higher concentration in the Sun Belt; 38% of its properties are in Florida, 11% in Arizona, and 10% in California. Equity Lifestyle targets owning properties in attractive retirement destinations. More than 70% of the company's properties are either age-restricted or have an average resident age over 55.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis marked its first two independent launches in 2025 for Tryngolza (for FCS) and Dawnzera (for HAE).